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The locus coeruleus (LC), the main noradrenergic cen- 
ter in the brain, participates in many neural functions, 
as diversa as memory and motor output, and is se- 
verely affected in several neurodegenerative disor- 
ders of the CNS. GDNF, a neurotrophlc factor intitially 
identified as dopaminotrophic, was found to be ex- 
pressed in several targets of central noradrenergic 
neurons in the adult rat brain. Grafting of genetically 
engineeredfibroblastsexpresslng high levelsof GDNF 
prevented >80% of the 8-hydroxydopamlne-induced 
degeneration of noradrenergic neurons in the LC in 
vivo. Moreover, GDNF induced a fasciculated sprout- 
ing and increased by 2.5-fold both tyrosine hydroxy- 
lase levels and the soma siie of lesioned LC neurons. 
These findings reveal a novel and potent neurotrophic 
activity of GDNF that may have therapeutic applica- 
tions in neurodegenerative disorders affecting central 
noradrenergic neurons, such as Alzheimer’s, Parkin- 
son’s, and Huntington’s diseases. 
Introduction 
The locus coeruleus (LC) is the most important noradren- 
ergic nucleus in the brain and provides widespread in- 
nervation to many regions of the CNS (Loughlin and Fal- 
Ion, 1985). This organization makes the LC a regulator of 
many essential functions, including motor output, vestibu- 
lar reflexes, vigilahce, attention, and memory (Barnes and 
Pompeiano, 1991). Furthermore, a marked lossof LC neu- 
rons and a severe impairment of some of these functions 
have been reported in the most important and devastating 
neurodegenerative disorders of the brain, including Alz- 
heimer’s (Tomlison et al., 1981; Bondareff et al., 1982; 
Hardy et al., 1985), Parkinson’s (Hassler, 1938; Forno, 
1966; Jellinger, 1991) Pick’s (Arima and Akashi, 1990) 
and Huntington’s (Zweig et al., 1986) diseases, Down’s 
syndrome (German et al., 1992), progressive supranu- 
clear palsy (Mann et al., 1963), and olivopontocerebellar 
atrophy (Tomonaga, 1983). 
Neurotrophic factors are polypeptides that promote sur- 
vival, differentiation, and phenotype of neurons. Neuro- 
trophin3 (NT-3), a member of the nerve growth factor fam- 
ily of neurotrophic factors, is a survival factor for LC 
noradrenergic neurons in vitro (Friedman et al., 1993). Fur- 
thermore, NT-3, but no other member of the neurotrophin 
family, has been shown to prevent the 6-hydroxydopamine 
(6OHDA)-induced degeneration of LC noradrenergic 
neurons in the adult brain in vivo (Arenas and Persson, 
1994). Surprisingly, however, homozygous mice carrying 
a deletion of the NT-3 gene showed no reduction in the 
number of neurons or in the level of tyrosine hydroxylase 
(TH) staining in the LC (Ernfors et al., 1994; Farifias et 
al., 1994) suggesting that other neurotrophic factors may 
be responsible for maintaining the survival and phenotype 
of central noradrenergic neurons. 
Glial cell line-derived neurotrophic factor (GDNF) a dis- 
tant member of the transforming growth factor 6 superfam- 
ily, was originally isolated by virtue of its ability to induce 
dopamine, but not GABA or serotonin, uptake and to. pro- 
mote the survival of dopaminergic neurons in cultures of 
embryonic ventral midbrain (Lin et al., 1993). Recent find- 
ings have extended the spectrum of biological activities 
of this molecule to different populations of neurons in both 
the peripheral and central nervous systems. In the periph- 
ery, GDNF has been reported to support the survival of 
neurons in nodose and sympathetic ganglia, as well as 
small subpopulations of embryonic sensory neurons in 
dorsal root and trigeminal ganglia (Henderson et al., 1994; 
Oppenheim et al., 1995; Trupp et al., 1995). GDNF has 
also been shown to modify the phenotype of sympathetic 
neurons in culture by increasing the expression of vaso- 
active intestinal peptide and preprotachykinin mRNAs and 
inducing robust bundle-like sprouting (Trupp et al., 1995). 
In the CNS, high doses of GDNF have been shown to 
prevent the axotomy-induced death of facial or spinal cord 
motorneurons (Henderson et al., 1994; Oppenheim et al., 
1995; Yan et al., 1995) and to protect adult nigral dopamin- 
ergic neurons from axotomy, 1-methyl4phenyl-1,2,3,6- 
tetrahydropyridine, or 6-OHDA toxicity (Beck et al., 1995; 
Kearns and Gash, 1995; Tomac et al., 1995). GDNF ad- 
ministration in the nigrostriatal system has been shown 
to induce sprouting from dopaminergic neurons, increase 
levels of dopamine, noradrenaline, and serotonin, and im- 
prove motor behavior (Tomac et al., 1995). GDNF mRNA 
expression has so far been documented only in the devel- 
oping rat striatum, the major target of nigral dopaminergic 
innervation, and in a few other regions, including hippo- 
campus and cortex (Schaar et al., 1993; Str6mberg et al., 
1993; Paulsen et al., 1994), but not in the normal adult brain. 
In this study, we have assessed the distribution of GDNF 
mRNA in the adult rat brain and its neurotrophic activity 
on LC noradrenergic neurons. Our results show that GDNF 
mRNA is expressed at low levels throughout the adult CNS 
and that GDNF prevents the death of LC neurons and 
displays remarkable neurotrophic activities on the pheno- 
type of central noradrenergic neurons in vivo. 
Results 
GDNF mRNA Is Widely Expressed 
in the Adult Brain 
We examined GDNF mRNA expression in adult brain re- 
gions using a sensitive RNase protection assay (Trupp et 
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Figure 1. Expression of GDNF mRNA in the Adult Rat Brain 
GDNF mRNA expression was analyzed by RNase protection. RNA (5 
ug) from the indicated brain regions was analyzed using a specific 
GDNFriboprobe. YeasttRNAwasusedasanegativecontrol. Striatum, 
septum, spinal cord, medulla, and thalamus showed the highest levels 
of GDNF mRNA expression in the brain. 
al., 1995). GDNF mRNA was found to be widely expressed 
in the adult rat brain, albeit at lower levels than in nonneu- 
ronal tissues (Trupp et al., 1995). GDNF mRNA was de- 
tected in thalamus, striatum, septum, cerebellum, spinal 
cord, and medullaoblongata (Figure 1). Lower levels were 
also found in cortex, hippocampus, cochlear nucleus, 
pons, mesencephalon, colliculi, and hypothalamus (Fig- 
ure 1). No GDNF mRNA was detected in the LC (Figure 
1). This widespread pattern of GDNF mRNA expression 
in the brain, including many areas innervated by noradren- 
ergic neurons, suggested that GDNF may be a neuro- 
trophic factor for LC noradrenergic neurons. 
Characterization of a Cell Line Genetically 
Engineered to Express High 
Levels of GDNF 
To assess the ability of GDNF to function as a neurotrophic 
factor for adult neurons in vivo, Fischer 344 rat 3T3 fibro- 
blasts were genetically engineered to produce GDNF in 
high amounts. These ceils, designated F3A-GDNF, ex- 
pressed high levels of GDNF mRNA up to 1 month after 
their implantation in the brain (Figure 2E), and like purified 
recombinant GDNF protein (Trupp et al., 1995) their con- 
ditioned media promoted survival of dissociated embry- 
onic day 10 chick sympathetic neurons (data not shown). 
F3A-GDNF cells produced more than 100 ng of GDNF per 
lo6 cells per day, as determined in a sympathetic neuron 
survival bioassay. Mock-transfected 3T3 cells (designated 
F3A-MT) expressed very low levels of GDNF mRNA (Fig- 
ure 2E), and conditioned media from these cells had no 
survival-promoting effect on dissociated sympathetic neu- 
rons (data not shown). 
GDNF Prevents the 6-OHDA-Induced Degeneration 
of Adult Noradrenergic Neurons In Vivo 
To assess the ability of GDNF to prevent the death and 
functional declineof neurons in the LC, noradrenergic neu- 
rons were selectively lesioned with an ipsilateral injection 
of &OHDA at the beginning of the dorsal bundle, 1 day 
after implantation of F3A-GDNF or F3AMT cells (Figures 
2A-2D). Seven days after surgery, brains were processed 
for histological analysis, and LC noradrenergic neurons 
were visualized using either antibodies against TH or cre- 
syl violet staining in serial sections through the entire LC. 
In animals with no cells implanted, the 6-OHDA lesion 
caused a selective loss of TH-positive noradrenergic neu- 
rons of about 50% in the LC compared with the contralat- 
eral side in the same animals (Figures 3 and 4A). This 
decrease was more pronounced in the anterior part of the 
nucleus, near the injection site of B-OHDA (Figure 48). As 
previously demonstrated (Arenas and Persson, 1994) the 
numbers of TH-positive and Nissl-stained neurons were 
shown to decrease to the same extent in this lesion model 
(compare Figures 4A and 4C), indicating a true loss of 
noradrenergic neurons after 6-OHDA injection. In nonle- 
sioned animals, unilateral grafting of FSA-GDNF or 
FSA-MT cells did not modify the number of noradrenergic 
neurons compared with the nontreated nucleus, indicating 
that the graft did not compromise the integrity of the LC. 
In the 6-OHDA-lesioned LC, implantation of F3A-MT cells 
did not prevent the decrease in the number of TH-positive 
and cresyl violet-stained neurons in the LC (Figures 3 and 
4) indicating that the graft per se had no survival- 
promoting effects on noradenergic neurons. In contrast, 
implantation of the FSA-GDNF cells prevented the degen- 
eration of about 80% of the lesioned neurons in the LC. 
The numbers of both TH-positive and cresyl violet-stained 
neurons were rescued to the same extent (Figures 4A and 
4C), indicating that GDNF prevented the 6-OHDA-induced 
death of LC noradrenergic neurons. In parallel experi- 
ments, NT3secreting fibroblasts (F3A-NT3) were shown 
to prevent the degeneration of noradrenergic neurons, as 
previously described (Arenas and Persson, 1994). NT-3 
prevented the decrease in the number of TH-positive neu- 
rons (ipsilateral, 598 & 50; contralateral, 670 + 19 [mean 
f SEMI; n = 3) and cresyl violet-stained LC neurons 
(ipsilateral, 620 f 44; contralateral, 708 f 23 [mean + 
SEMI; n = 3) after lesion to an extent similar to GDNF. 
GDNF Promotes Phenotypic Changes in Adult LC 
Noradrenergic Neurons 
FSA-GDNF, F3A-NT3, or FSA-MT cells were unilaterally 
grafted posterolateral to the LC (see Figures 2A-2C), and 1 
day later, some of the animals received ipsilateral6OHDA 
injections rostra1 to the LC. Seven days after surgery, 
brains were processed for TH immunohistochemistry, and 
the phenotype of LC noradrenergic neurons was analyzed 
in serial sections at the level of the grafts. 
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Figure 2. Characterization and Grafting of a GDNF-Producing Fibroblast Cell Line (FSA-GDNF) 
(A) Camera lucida drawing of three representative cresyl violet-stained coronal sections through the anteroposterior extension of the LC. The 
upper drawing corresponds to a section through the anterior LC (0.4 mm caudal to interaural line), the middle drawing to the medial LC (0.7 mm 
caudal to interaural line), and the lower drawing to the posterior LC (1 mm caudal to interaural line). 
(B) Photomicrograph of the posteromedial LC (interaural -0.3) showing the grafting site, lateral to the LC. V, fourth ventricle. 
(C and D) High power photomicrographs of cresyl violet-stained grafts illustrating the survival of F3A-MT (C) and F3A-GDNF (D) fibroblasts 1 
week after implantation and COHDA lesion. 
(E) Expression of GDNF mRNA in the FM-MT and F3A-GDNF cells before and after grafting. RNA (2 ug) from GDNF-expressing cells (FJA-GDNF) 
or mock-transfected cells (F3A-MT) in culture (in vitro) or 1 month after implantation in the brain (in vivo) was analyzed by RNase protection assay. 
The levels of GDNF mRNA expressed by the cell lines are compared with that in 10 ug of total RNA from postnatal day 1 kidney, one of the organs 
with the highest levels of GDNF mRNA in the rat. Yeast tRNA was used as a negative control. 
(F) Schematic drawing of the position of the cell lines (GRAFT) and S-DHDA injection relative to the LC. Note that, in this paradigm, GDNF is 
delivered from the posterolateral part of the nuclei, and the lesion, placed anterior to the LC, induces an anterior to posterior gradient of cell loss 
(Arenas and Perseon, 1994). Both manipulations were performed unilaterally, leaving the contralateral side intact. 
Figure 3. Effect of GDNF on Survival of Noradrenergtc Neurons in the LC 
Photomicrographs of sections through the anterior part of the LC stained with a monoclonal antibody against TH. (A) control side; (B) Q-GHDA 
lesioned side; (C) Q-OHDA lesioned LC implanted with the control cell line (F3A-MT); (0) Q-DHDA lesioned LC implanted with the GDNF-expressing 
cell line (FSA-GDNF), showing an almost complete prevention of 6OHDA-induced cell death. Bar, 200 Wm. 
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Figure 4. Effect of GDNF on the Number of Noradrenergic Neurons 
in the LC 
(A) Number of TH-positive neurons in the LC after implantation of 
GDNF-expressing (FMGDNF) or mock-transfected (FSA-MT) cell 
lines in the intact or SOHDA lesioned LC. 
(B) Anteroposterior distribution of TH-positive neurons in the LC after 
lesion and grafting of F3AMT or F3A-GDNF cells. 
(C) Number of cresyl violet-stained neurons in the LC after lesion and 
grafting of FSA-MT or FBA-GDNF cells. 
Values represent mean + SEM of the number of TH-positive cells in 
the LC. Asterisk, p < .Ol versus unlesioned side; double asterisk, p 
< .Ol versus lesion with or without control graft (FSA-MT) (two-tailed 
Student’s t test). 
implantation of F3A-MT or F3A-NT3 cells had no effect 
on the cytoplasmic area of TH-positive neurons (see Fig- 
ure 6) nor did they induce sprouting from noradrenergic 
neurons in the intact LC (see Figure 8), indicating that 
neither the cells per se nor NT-3 promotes these pheno- 
typic parameters in LC noradrenergic neurons. In contrast, 
F3A-GDNF cells induced a 70% increase in the cyto- 
plasmic area of TH-positive neurons, compared with the 
contralateral side (Figures 56 and 6) and a mild increase 
in sprouting from noradrenergic neurons in the ipsilateral 
LC (see Figure 8). 
In nongrafted animals, 6-OHDA injections did not affect 
the soma size of the surviving TH-positive neurons at any 
level of the LC, nor did it selectively kill neurons of any 
particular size (Figures 5 and 6). In addition, the intensity 
of TH staining in the cell bodies of LC neurons was un- 
changed compared with the control side (Figure 7) al- 
though TH staining was increased in varicosities close to 
cell bodies (data not shown). Implantation of the F3A-MT 
or F3A-NT3 cells in lesioned animals had no effect on 
the size of the soma (Figures 5B and 6), the levels of TH 
staining (Figure 7), or sprouting (Figure 8) of LC noradren- 
ergic neurons. In contrast, GDNF treatment induced adra- 
matic increase in the area of the soma of TH-positive neu- 
rons (see Figures 58 and 6) and the levels of TH staining 
(Figure 7) as well as promoted pronounced bundle-like 
sprouting (Figure 8F). Compared with the nonlesioned ani- 
mals, the lesion appeared to potentiate the effects of 
GDNF on both hypertrophy and sprouting of LC neurons 
(compare Figures 8E and 8F). 
Discussion 
In the present study, we show that GDNF prevents the 
degeneration of adult central noradrenergic neurons of 
the LC in vivo. Although survival was comparable to that 
previously reported after NT-3 administration (Arenas and 
Persson, 1994) GDNF, but not NT-3, induced a remark- 
able hypertrophy as well as a dramatic increase in TH levels 
and sprouting of noradrenergic neurons. Thus, GDNF ap- 
pears to be a very powerful neurotrophic factor for adult 
central noradrenergic neurons, capable of promoting both 
the survival and phenotype of LC neurons. Since the levels 
of GDMF mRNA expression have been found to be higher 
in the developing brain than in the adult (Schaar et al., 
1993; Str&nberg et al., 1993; Poulsen et al., 1994), our 
data suggest that GDNF, or a combination of GDNF and 
NT-3, may play a central role in the maturation and survival 
of developing noradrenergic neurons. Analysis of GDNF+ 
mutant mice may shed light on this issue. 
In the experimental paradigm used in the present study, 
the 6-OHDA lesion generates a gradient of cell death, be- 
ing more pronounced in the anterior part of the nucleus 
than in the posterior part (Arenas and Persson, 1884; and 
Figure 48). It is also conceivable that the graft, posterolat- 
eral to the LC, generates a caudal to rostra1 gradient of 
concentration of the factor. This gradient could be respon- 
sible for elevated effects of GDNF on hypertrophy and 
sprouting in the posteromedial LC (close to the graft) but 
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Figure 5. Effect of CDNF on the Stze of the Soma of TH-Poeitive Neurons in the LC 
In the nonfeaioned LC, F3A-DDNf cefls (8) induced an increase in the soma size of noradrenergic neurons (arrowheads) compared with the 
side (A). In the &DHDA lesioned LC, the F3A-DDNF cell line (D), but not the F3A-MT cell line (C), induced a hypertrophy of noradrenergic r-r 
The borders of the grafts (g) are labeled with dashed lines. Photomicrographs in (A) and (3) were taken from the ventrocaudal LC. Photomicrc 
in (C) and (D) were taken from the dorsocaudal LC. Bars, 16 urn (A and B), 32 pm (C and D). 
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Figure 6. Effect of GDNF on the Cytoplasmic Area of Lesioned and 
Unlesioned TH-Positive Neurons in the LC 
GDNF increased the size of noradrenergic neurons in the 6-OHDA 
lesioned LC to a greater extent than in nonlesioned nuclei. Values 
represent the mean area (in square micrometers) f SEM (n = 3-4). 
Asterisk, p < .Ol versus unlesioned side (two-tailed Student’s t test). 
control 
eurons. 
lgraphs 
not in the anterior part of the LC (close to the lesion site). 
Because complete prevention of cell death was observed 
in the anterior part of the LC, higher doses of GDNF may 
be required to promote hypertrophy and sprouting as com- 
pared with survival. In this context, it is worth noting that 
most of the previous in vivo studies used doses of GDNF 
up to two orders of magnitude higher than those used 
here; this may have precluded the observation of different 
dose requirements for distinct biological activities. 
The dramatic effects of GDNF on the phenotype of nor- 
adrenergic neurons, particularly the hypertrophy, and the 
nearly complete protection of LC neurons from 6-DHDA- 
induced degeneration suggest that GDNF exhibits broader 
and more pronounced neurotrophic activities on noradren- 
ergic neurons than those previously reported on dopamin- 
ergic neurons (Beck et al., 1995; Kearns and Gash, 1995; 
Tomac et al., 1995). In the nigrostriatal system, administra- 
tion of GDNF was shown to increase the levels not only 
of dopamine but alsoof noradrenaline(Tomac et al., 1995). 
Interestingly, however, the increase in noradrenaline was 
seen only in the substantia nigra, a target of LC noradren- 
ergic neurons, and not in the striatum, which is not inner- 
Figure 7. Effect of GDNF on the Intensity of TH lmmunostaining in 
Neurons of the LC 
The FSA-GDNF cell line, but not the F3A-NT3 or F3A-MT cell line, 
increased the levels of TH immunostaining in the LC at 7 days after 
lesion. Note that the intensity of the staining is a semiquantitative 
measure and is expressed in relative values. C, control locus; L, 
COHDA lesioned LC; L + MT, leslonsd LC grafted with the mock- 
transfected cell line; L + NT3, lesioned LC with a NT-Sproducing graft 
(Arenas and Persson, 1994); L + GDNF, lesion plus grafting of the 
GDNF-transfected cell line. Double asterisks, p < .Ol versus any of 
the other conditions (two-tailed Student’s t test). 
vated by LC neurons (Loughlin and Fallon, 1985). Our 
findings suggest that, in this case, GDNF may have in- 
duced a neurotrophic response on LC neurons via norad- 
renergic terminals in the substantia nigra, reinforcing the 
notion that GDNF is a neurotrophic factor for LC noradren- 
ergic neurons. 
Interestingly, GDNF elicited a more profound induction 
of the phenotype of noradrenergic neurons following 
6-OHDA injection than in the nonlesioned LC. This result 
suggests that noradrenergic neurons may respond to the 
lesion by increasing the expression of GDNF receptors, 
perhaps as part of a lesion-induced mechanism to in- 
crease responsiveness to low levels of neurotrophic factor. 
In this context, it is worth noting that, while the lesion in- 
creased the responsiveness of LC neurons to GDNF, lev- 
els of GDNF mRNA in target areas of noradrenergic neu- 
rons, or in the LC itself, were unaffected by the lesion 
(E. A., M. T., P.A., and C. F. I., unpublished data). On the 
other hand, the increased responsiveness after the lesion 
could also be the result of elevated levels of downstream 
elements in the GDNF signaling pathway. Regardless of 
the mechanism by which 6-OHDA induces GDNF respon- 
siveness in the LC, the hypertrophy, induction of TH, and 
sprouting of nerve terminals observed in surviving norad- 
renergic neurons after GDNF administration point to an 
increased functional capacity of these cells and suggest 
that GDNF may be a promising candidate molecule to 
prevent and compensate for the degeneration of central 
noradrenergic neurons. 
Degeneration of basal forebrain cholinergic neurons is 
a well-known pathological feature of Alzheimer’s disease 
(Davies and Maloney, 1976; Whitehouse et al., 1982; Fibi- 
ger, 1991). However, other populations of neurons are also 
affected early, constantly, and severely by the disease, 
such as the noradrenergic neurons of the LC (Tomlison 
et al., 1981; Bondareff et al., 1982; Hardy et al., 1985). In 
particular, the greatest loss of noradrenergic neurons in 
Alzheimer’s disease, as well as in Down’s syndrome and 
Parkinson’s disease with dementia, occurs within the ante 
romedial portion of the nucleus, corresponding to cortical 
projecting neurons (Marcynuik et al., 1986; Zweig et al., 
1988; Chan-Palay and Asan, 1989; German et al., 1992). 
The 8-OHDA lesion model used in this study (Arenas and 
Persson, 1994) mimics those disorders not only in the ros- 
tral pattern of neuronal loss within the LC but also in the 
proposed mechanism of cell death, namely oxidative 
stress (Beal et al., 1993; Behl et al., 1994). In agreement 
with the role of these neurons in attention and memory 
(Harley, 1991), degeneration of LC neurons has been cor- 
related with dementia in both Alzheimer’s disease (Ger- 
man et al., 1992) and Parkinson’s disease (Bondareff et 
al., 1982; Mann and Yates, 1983; Gaspar and Gray, 1984; 
Chui et al., 1986; Cash et al., 1987; Zweig et al., 1993). 
It has been known for a long time that degeneration 
of neuromelanin-containing neurons in the brain, namely 
nigral dopaminergic neurons (Pakkenberg and Brody, 
1965; Hornykiewicz and Kish, 1987; Hirsch et al., 1988) 
and LC noradrenergic neurons (Hassler, 1938; Halliday 
et al., 1990; Jellinger, 1991), is a prominent pathological 
feature of idiopathic Parkinson’s disease. In this case, neu- 
ronal loss in the LC affects all levels of the nucleus to a 
similar extent (Chan-Palay and Asan, 1989; Chan-Palay, 
1991; German et al., 1992; Zweig et al., 1993), and it is 
accompanied by noradrenergic denenration of several 
structures, including cerebellum, spinal cord, and cortical 
motor areas. Accordingly, degeneration of LC noradrener- 
gic neurons has been reported to contribute to the motor 
alterations and to be responsible for the propioceptive defi- 
cits observed in Parkinson’s disease (Schneider et al., 
1987; Gaspar et al., 1991). Furthermore, loss of dopamin- 
ergic neurons, decreased dopamine content in striatum, 
and parkinsonian signs induced by dopaminergic lesions 
are potentiated by simultaneous lesioning of the LC in 
monkeys and mice (Mavridis et al., 1991; Marien et al., 
1993). Thus, GDNF, by inducing both individual and syner- 
gistic trophic responses on central dopaminergic and nor- 
adrenergic neurons, may constitute a very powerful thera- 
peutic candidate for Parkinson’s disease. 
In summary, we have found widespread expression of 
GDNF in the adult CNS and a novel and potent neuro- 
trophic activity of GDNF on LC noradrenergic neurons. 
Although it is presently unknown why the neurons in the 
LC are so vulnerable and degenerate in so many diseases, 
the ability of GDNF to promote both the survival and phe- 
notype of LC neurons suggests that this protein may be 
a physiological trophic factor for central noradrenergic 
neurons with potential therapeutic application in neurode- 
generative disorders affecting the LC. 
Experimental Procedures 
FtNasa Protaction Assay 
Assays were performed using the RPAII Ribonuciease Protection 
Assay Kit (Ambion) following the manufacturers’ recommendations. 
GDNF and glyceraldehyde Sphosphate dehydrogenase (GAPDH) 
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Figure 8. Effect of GDNF on Spro&ng of Moradrenergic Neurons in the LC 
Photomicrographs of sections through the pastemmedial part of the LC stained with a monoclonal antibody against 
lesioned LC; (C) LC implanted with the control cell lie (F3A-MT); (0) grafting of the control cell line (F3A-MT) in 
not induce sprouting toward the graft; (E) LC implanted with the GDNF-expressing cell line (F3A-GDNF). showing a n 
lesioned LC implanted with the GDNF-expressing cell line (F3AGDNF). Note the prominent bundle-like sprouting 1 
of strongly stained hypertrophic neurons. Note also that the exposure of the photomicrograph in (F) is adjusted to 
bodies are overexposed owing to the increase in the levels of TH staining induced by GDNF. The dashed lines d 
(g). Arrowheads point to sprouts entering the graft. Bar, 32 pm. 
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cRNA probes were labeled with [cI-~PJCTP by in vitro transcription. 
The probe was hybridized to 2-10 ug of RNA extracted from different 
brain regions or from cell lines in vivo or in culture (n = 2-3). Protected 
cRNA fragments were separated on 4% polyacrylamide gels under 
denaturing conditions, followed by film autoradiography, as described 
(Trupp et al., 1995). 
GDNF Cell Line 
A rat GDNF cDNA was cloned into the Pstl siteof the plasmid MRE-(4x)- 
OVEC (Westin et al., 1987). This plasmid was linearized and cotrans- 
fected with pBMN-Neo’ and pCH1 IO-lac2 (Pharmacia) pfasmids (in a 
molar ratio of IO:1 :I) into Fischer 344 rat 3T3 fibrobfasts, using the 
calcium phosphate/glycerol technique. Transfected cells were se- 
lected with the neomycin analog G-41 8, isofated, amplified and subse- 
quently analyzed. Fischer rat 3T3 cell lines, FM-MT, F3AGDNF, and 
F3A-NT3, were grown in Dulbecco’s modified Eagle’s medium with 
10% fetal calf serum, 1 mg/ml penicillin-streptomycin, 1 mg/ml gluta- 
mine, and 200 uglml G-418. 
Surgery 
Male Fischer 344 rats (200-300 g), housed and treated according to 
institutional guidelines, were anesthesized with thiobarbital. Cultured 
fibroblasts were collected with Cell Lifters (Costar), washed twice, 
counted, and resuspended in Dulbecoo’s modified Eagle’s medium 
without fetal calf serum. Subsequently, 0.75 x lo8 cells in 3 ul of 
medium were sterotaxically injected dorsolateral to the LC at the follow- 
ing coordinates relative to lambda and the dural surface: AP = -3.1 
mm, L = +1.5 mm, DV = -6mm, with the incisor bar set at -10 mm. 
The cells typically formed a small focal tumor of about 0.5 x 1 mm 
along the final tract of the injection canula, which was located not 
further than 100 jrrn lateral from the caudal end of the LC. The location 
chosen for the injections preserved the integrity of the nucleus and 
allowed the neurons to access the proteins secreted by the cell lines. 
One day after the implant, some of the rats were reanesthetized, 
treated with 4 mglkg of amfonelic acid (intraperitoneally), and sterotaxi- 
tally injected with 8 pg of 6-OHDA (Sigma) in the dorsal bundle, 100 
urn lateral and inferior to the rostra1 end of the locus, at the following 
coordinates: AP = 1.5 mm, L = 1.2 mm, DV = -7.1 mm relative 
to lambda and the dural surface, with the incisor bar set at 5 mm 
over 0. 
Histology 
Seven days after surgery, rats were perfused and the brains were 
processed for TH immunohistochemistry or cresyl violet staining, as 
described (Arenas and Persson, 1994). In brief, frontal serial cryostat 
sections (14 pm thick) were obtained covering the entire LC. Sections 
every 98 urn were processed for TH immunohistochemistry and cresyl 
violet staining. Only brains that showed a correct position of implant 
and lesion sites were included in the study. Neurons through all the 
dorsal LC showing a clearly TH-positive fusiform or multipolar cyto- 
plasm around a nonstained nuclei were counted as positive. In cresyl 
violet-stained sections, neurons showing a nucleus with a clear nu- 
cleoplasm and prominent nucleolus and a stained fuafform or multipo- 
lar cytoplasm were counted as positive. Counts were performed in 
blind duplicate or triplicate determinations using a Nikon microphot- 
FXA microscope (100 x magnification). Three to four animals receiving 
graft alone and six to seven animals receiving &ion alone or lesion 
plus graft were analyzed. Positive neuron counts were taken for statisti- 
cal analysis and were not corrected for split nucleoli. 
The intensity of TH staining was measured with the spot photometer 
of the microscope from randomly chosen TH-positive stained cyto- 
plasms in the LC. Only measures of neurons that lay in the linear 
range of detection were used. About 200 neurons were measured for 
every experimental condition, with the exception of animals receiving 
6-OHDA and the F3A-NT3 cell line (100 neurons); 4 cells were mea- 
sured per section (100 x magnification) in 6-8 serial sections per brain 
at the level of the graft, in 3-8 animals per condition. The background 
level of fluorescence, measured lateral to the LC, was subtracted from 
the values obtained in the cytoplasms of TH-positive neurons at every 
level. 
The cytoplasmic area of TH-positive neurons was measured using 
a Quantimet 570 analysis system and a JVC KY F30 video camera, 
coupled to a Nikon FXA microscope at 100 x magnification. The level 
of the cutoff was set for every neuron to fit its size precisely. This 
setting usually varied very few units from the experimental neurons 
in the ipsilateral side to the control neurons in the contralateral side. 
About 100 clearly defined TH-positive somas in the LC were randomly 
selected. We measured 5 neurons on each side per level, from serial 
sections at 6-8 different levels per animal through the posterior and 
medial LC, in 3-4 animals per experimental condition. 
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